190,536 Shares in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 190,536 shares of the biopharmaceutical company’s stock, valued at approximately $875,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.32% of Vanda Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its holdings in Vanda Pharmaceuticals by 17.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 3,370 shares during the last quarter. ProShare Advisors LLC increased its holdings in Vanda Pharmaceuticals by 32.4% in the fourth quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 4,599 shares in the last quarter. Brandywine Global Investment Management LLC increased its stake in shares of Vanda Pharmaceuticals by 13.9% in the 4th quarter. Brandywine Global Investment Management LLC now owns 39,390 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 4,820 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Vanda Pharmaceuticals by 2.1% during the 4th quarter. American Century Companies Inc. now owns 300,276 shares of the biopharmaceutical company’s stock worth $1,438,000 after purchasing an additional 6,079 shares in the last quarter. Finally, Northern Trust Corp increased its position in Vanda Pharmaceuticals by 1.3% in the 4th quarter. Northern Trust Corp now owns 507,442 shares of the biopharmaceutical company’s stock valued at $2,431,000 after buying an additional 6,283 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Trading Down 1.6%

VNDA stock opened at $4.19 on Friday. Vanda Pharmaceuticals Inc. has a 1-year low of $3.81 and a 1-year high of $5.56. The stock has a market cap of $246.93 million, a P/E ratio of -3.71 and a beta of 0.68. The stock’s fifty day simple moving average is $4.64 and its two-hundred day simple moving average is $4.54.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.12). Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%. The company had revenue of $52.59 million during the quarter, compared to the consensus estimate of $54.77 million. As a group, analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Vanda Pharmaceuticals

In other news, Director Stephen Ray Mitchell sold 7,000 shares of Vanda Pharmaceuticals stock in a transaction on Friday, June 13th. The stock was sold at an average price of $4.59, for a total value of $32,130.00. Following the completion of the transaction, the director directly owned 97,082 shares in the company, valued at approximately $445,606.38. The trade was a 6.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of Vanda Pharmaceuticals stock in a transaction on Wednesday, May 21st. The shares were bought at an average cost of $4.40 per share, with a total value of $44,000.00. Following the acquisition, the chief executive officer directly owned 2,325,731 shares in the company, valued at approximately $10,233,216.40. This represents a 0.43% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 10.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on VNDA shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 target price on shares of Vanda Pharmaceuticals in a report on Wednesday, May 14th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a report on Wednesday, May 7th. Finally, Wall Street Zen lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Saturday.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.